Singer K, Cheng M N
Br Med J. 1971 Oct 2;4(5778):22-5. doi: 10.1136/bmj.4.5778.22.
Thiopropazate (Dartalan) was found to be significantly more effective than a placebo in relieving dyskinesia in 23 patients with functional psychosis and persistent dyskinesia associated with prolonged phenothiazine therapy. Each patient whose dyskinesia had persisted unchanged for at least one month after phenothiazine withdrawal received thiopropazate by mouth for three weeks and the placebo for a similar period. Patients were evaluated before the trial, at three weeks, and at six weeks.The drug also improved psychotic behaviour. Possible side effects, which were generally mild, were noted in eight patients, of whom six had Parkinsonism and four drowsiness. None had side effects while on the placebo.The findings indicate that thiopropazate is of value in persistent dyskinesia associated with prolonged phenothiazine intake-a condition hitherto unresponsive to other treatment. Further research is required to determine the long-term effectiveness of the drug.
在23例患有功能性精神病且伴有因长期服用吩噻嗪类药物治疗而导致持续性运动障碍的患者中，发现硫丙哌嗪（达他兰）在缓解运动障碍方面比安慰剂显著更有效。在停用吩噻嗪类药物后运动障碍持续至少一个月未改变的每位患者，口服硫丙哌嗪三周，然后服用安慰剂同样时长。在试验前、三周时和六周时对患者进行评估。该药物还改善了精神病行为。8例患者出现了通常较为轻微的可能副作用，其中6例有帕金森症，4例有嗜睡。服用安慰剂时无人出现副作用。研究结果表明，硫丙哌嗪对与长期服用吩噻嗪类药物相关的持续性运动障碍有价值——这是一种迄今对其他治疗无反应的病症。需要进一步研究以确定该药物的长期疗效。
